503A vs. 503B Compounding: What Every Telehealth Founder Should Know

If you're launching a program built on compounded medications—GLP-1s, hormones, peptides—you'll quickly run into two terms: 503A and 503B. They describe different kinds of pharmacies operating under different rules. Knowing which is which keeps your program on solid ground and helps you ask the right questions of any pharmacy partner.

The names come from sections of the federal Food, Drug, and Cosmetic Act, added by the Drug Quality and Security Act. You don't need to memorize the statute—but you do need to understand what each type of pharmacy can and can't do.

503A pharmacies

A 503A pharmacy compounds medications for an individual patient based on a specific prescription. This is the model most direct-to-patient telehealth programs rely on: a provider writes a prescription for a named patient, and the pharmacy prepares that patient's medication. 503A pharmacies are primarily overseen by state boards of pharmacy.

When 503A fits

• Direct-to-patient telehealth programs with individual prescriptions
• Personalized formulations and dosing
• Most GLP-1, hormone, and peptide programs run through licensed 503A partners

503B outsourcing facilities

A 503B outsourcing facility can compound in larger batches without a patient-specific prescription and is held to more stringent, FDA-registered manufacturing standards (current good manufacturing practices). These facilities typically serve clinics and healthcare organizations that need volume and office stock.

When 503B fits

• Clinics and organizations buying office stock
• Higher-volume, batch production needs
• Settings that require FDA-registered manufacturing standards

The key differences at a glance

• Prescription: 503A requires a patient-specific prescription; 503B does not
• Scale: 503A compounds per patient; 503B compounds in batches
• Oversight: 503A is state-board regulated; 503B is FDA-registered under stricter manufacturing standards
• Typical use: 503A serves direct-to-patient telehealth; 503B serves clinics and office stock

What it means for your brand

Match the pharmacy type to how your program actually dispenses. Most direct-to-patient telehealth brands run on 503A partners, but the right answer depends on your model. Whatever you choose, three things matter:

• Confirm licensing in every state you ship to
• Prioritize partners with strong quality controls and clear documentation
• Make sure dispensing and shipping follow the rules for each patient's state

Compliance considerations

Compounded medications occupy a nuanced regulatory space, and the rules evolve. Working with licensed, reputable partners—and keeping clear documentation of dispensing—protects both your patients and your brand. This is precisely the kind of complexity a vetted, pre-integrated pharmacy network is meant to absorb, so you're not negotiating individual contracts or auditing licenses yourself.

Key takeaways

• 503A compounds per patient from a specific prescription; 503B compounds in batches under FDA-registered standards.
• Most direct-to-patient telehealth runs on licensed 503A pharmacies.
• Always confirm state licensing and quality controls, whichever type you use.
• You don't need to become a pharmacy expert—but your platform should already have vetted, licensed partners integrated.

MDLaunchr connects your brand to vetted, licensed compounding partners with direct-to-patient fulfillment—so the medication side of your program is handled correctly without you negotiating a single contract.